Prospect News: News for European Medco Development 4 Sarl

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with E > Issuers starting with E, BK only > All stories on European Medco Development 4 Sarl > Stories on European Medco Development 4 Sarl, BK only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

European Medco Development 4 Sarl

12/19/2024	BK	Moody’s stabilizes Axplora outlook
8/3/2023	BK	Fitch downgrades Axplora
7/28/2023	BK	Moody's moves Axplora view to negative
11/5/2021	BK	PharmaZell revises €215 million term loan B OID to 99.25
11/4/2021	BK	PharmaZell changes €215 million term loan B OID talk to 98.75-99
10/27/2021	BK	PharmaZell launches €215 million add-on term loan B at 98.5 OID
6/15/2020	BK	Moody’s assigns PharmzZell B2
6/9/2020	BK	Fitch assigns European Medco Development B, loan B+

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.